DIVA Laboratories, Ltd. (TPEX:4153)
40.65
+0.10 (0.25%)
Aug 13, 2025, 1:30 PM CST
Paramount Global Revenue
DIVA Laboratories had revenue of 235.02M TWD in the quarter ending June 30, 2025, with 5.37% growth. This brings the company's revenue in the last twelve months to 859.02M, up 0.17% year-over-year. In the year 2024, DIVA Laboratories had annual revenue of 862.32M, down -3.53%.
Revenue (ttm)
859.02M
Revenue Growth
+0.17%
P/S Ratio
2.78
Revenue / Employee
5.58M
Employees
154
Market Cap
2.38B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 862.32M | -31.52M | -3.53% |
Dec 31, 2023 | 893.84M | -55.36M | -5.83% |
Dec 31, 2022 | 949.20M | 236.97M | 33.27% |
Dec 31, 2021 | 712.23M | -24.69M | -3.35% |
Dec 31, 2020 | 736.93M | 20.76M | 2.90% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Caliway Biopharmaceuticals | 44.83M |
PharmaEssentia | 11.34B |
Bora Pharmaceuticals Co., LTD. | 21.32B |
Lotus Pharmaceutical | 19.12B |
Oneness Biotech | 112.57M |
Polaris Group | 87.67M |
Center Laboratories | 1.63B |
Lumosa Therapeutics | 37.25M |